InvestorsHub Logo
Followers 68
Posts 11751
Boards Moderated 1
Alias Born 01/09/2007

Re: sokol post# 64

Friday, 11/18/2022 1:20:07 PM

Friday, November 18, 2022 1:20:07 PM

Post# of 83
they have over 100M in cash and securities. i don't think any of that matters. What matters is that they're charging $200k for a treatment that doesn't even offer a cure, only a very short term delay of disease progression. I'm surprised the FDA even approved it, but i bought back in when they did, assuming they truly believed in this drug. Only PRVB can struggle to close even on a day they get a major drug approved. Every other pharma doubles or triples on this news